What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.

In this week’s episode of "The Top Line," the Fierce Biotech editorial team reflects on the process of distilling more than 150 high-quality entries into the final Fierce 15 list. The team discusses how the ambitions of these companies are higher than ever and looks back on some of its conversations with the winners, covering everything from cutting-edge antibody research and novel fertility treatments to innovative ways to source radioisotopes.

To learn more about the topics in this episode: 
Introducing Fierce Biotech's 2026 Fierce 15 
Regeneron backs $75M series A for antibody upstart Infinimmune 
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
Fierce Biotech at London Life Sciences Week: Learn more and register 
Learn more about the Fierce Vanguard Awards Gala

What does it mean to be a Fierce 15 biotech in 2026? With this year&rsquo;s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector. In this week&rsquo;s episode of "The Top Line," the Fierce Biotech editorial team reflects on the process of distilling more than 150 high-quality entries into the final Fierce 15 list. The team discusses how the ambitions of these companies are higher than ever and looks back on some of its conversations with the winners, covering everything from cutting-edge antibody research and novel fertility treatments to innovative ways to source radioisotopes.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/introducing-fierce-biotechs-2026-fierce-15" data-processed-url="true">Introducing Fierce Biotech's 2026 Fierce 15</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/biotech/regeneron-backs-75m-series-antibody-upstart-infinimmune" data-processed-url="true">Regeneron backs $75M series A for antibody upstart Infinimmune</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/biotech/expedition-lands-115m-series-b-advance-phase-2-copd-trial" data-processed-url="true">Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/beacon-lights-path-fda-approval-pivotal-trial-win-rare-vision-loss-gene-therapy" data-processed-url="true">Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy</a></li>
<li><a href="https://biotechlondon.fiercelifesciences.com/">Fierce Biotech at London Life Sciences Week: Learn more and register&nbsp;</a></li>
<li><a href="https://fiercevanguard.fiercelifesciences.com/">Learn more about the Fierce Vanguard Awards Gala</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;